Current strategies in the treatment of Parkinson's disease and a personalized approach to management

Expert Review of Neurotherapeutics

Volumn 9, Issue 12, 2009, Pages 1781-1789

  Diaz, Nancy L ^a   Waters, Cheryl H ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Dopamine agonists; Levodopa; Neuroprotection; Parkinson's disease; Psychosis

Indexed keywords

AMANTADINE; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CLOZAPINE; DOMPERIDONE; DONEPEZIL; ENTACAPONE; FLUDROCORTISONE; GALANTAMINE; LEVODOPA; MIDODRINE; OLANZAPINE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RASAGILINE; RISPERIDONE; RIVASTIGMINE; ROPINIROLE; SELEGILINE; TACRINE; TOLCAPONE;

BRAIN DEPTH STIMULATION; CLINICAL TRIAL; CONSTIPATION; DEMENTIA; DISEASE COURSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MEGADOSE; HUMAN; HYPERSALIVATION; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

ANTIPARKINSON AGENTS; AUTONOMIC NERVOUS SYSTEM DISEASES; CHOLINERGIC ANTAGONISTS; CLINICAL TRIALS, PHASE II AS TOPIC; DEEP BRAIN STIMULATION; DEPRESSION; DOPAMINE AGONISTS; HUMANS; MONOAMINE OXIDASE INHIBITORS; MULTICENTER STUDIES AS TOPIC; PARKINSON DISEASE; PSYCHOTIC DISORDERS;

EID: 72049126077     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.117     Document Type: Review

References (54)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 5, 525-535 (2006).
2. Lilienfeld DE, Perl DP. Projected neurodegeneration disease mortality in the United States, 1990-2040. Neuroepidemiology 12, 219-228 (1993).
3. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321, 1364-1371 (1989).
4. Giladi N, McDermont MP, Fahn S et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 56, 1712-1721 (2001). (Pubitemid 32574572)
5. Miyasaki HM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease (an evidence based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58, 11-17 (2002). (Pubitemid 34041931)
6. Clarke A, Johnson ES, Mallard N et al. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J. Neural Transm. 110, 1257-1271 (2003). (Pubitemid 37500747)
7. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM. Zydis selegiline study group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov. Disord. 19, 426-432 (2004). (Pubitemid 38559645)
8. Parkinson Study Group. A controlled, randomized, delayed start study of rasagiline in early Parkinson disease: the TEMPO study. Arch. Neurol. 59, 1937-1943 (2004).
9. Parkinson Study Group. A controlled, randomized, delayed start study of rasagiline in early Parkinson disease. Arch. Neurol. 61, 561-566 (2004).
10. Hauser RA, Lewy MF, Howard I et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov. Disord. 24(4), 564-573 (2008).
11. Olanow CW, Hauser RA, Jankovic J et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics. Mov. Disord. 23 (15), 2194-2201 (2008).
12. Olanow CW, Rascol O, Hauser R et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361(13), 1268-1278 (2009).
13. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations (the PRESTO study). Arch. Neurol. 62, 241-248 (2005).
14. Rascol O, Brook DJ, Melamed E et al.; LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting Effect in Adjunctive Therapy with Rasagiline Given Once Daily, study): a randomised, double-blind, parallel. Lancet 365, 947-954 (2005). (Pubitemid 41071428)
15. Parkinson Study Group. A randomized, controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD study. Clin. Neuropharmacol. 23(1), 34-44 (2000).
16. Parkinson Study Group. Long-term effect of initiating pramipexole vs. levodopa in early Parkinson disease. Arch. Neurol. 66(5), 563-570 (2009).
17. Katzenschlager R, Head J, Schrag A, Ben-Shlmo Y, Lees AJ. Parkinson's Disease Research Group of the United Kingdom. Fourteen-year final report of the randomized PDRG-UK trial comparing initial treatments in PD. Neurology 71, 474-480 (2008).
18. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson's disease: non-l-dopa-responsive problems predominate at 15 years. Mov. Disord. 20, 190-199 (2005). (Pubitemid 40361122)
19. Weiner WJ, Reich SG. Agonist or levodopa for Parkinson disease?: ultimately, it doesn't matter; neither is good enough. Neurology 71(7), 470-471 (2008).
20. Pahwa R, Stacy MA, Factor SA et al. Ropinirole 24 hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68, 1108-1115 (2007). (Pubitemid 46559844)
21. Nashatizadeh MM, Lyons KE, Pahwa R. A review of ropinirole prolonged release in Parkinson's disease. Clin. Interv. Aging 4, 179-186 (2009).
22. Thomas A, Iacono D, Luciano AL, Armellio K, Di Iorio A, Onofrj M. Duration of amantadine benefit in dyskinesia of severe Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 75, 141-143 (2004). (Pubitemid 38091285)
23. Fabrizio S, Tagliati M, Olanow CW. Treatment of levodopa induced motor complications. Mov. Disord. 23(3), S599-S612 (2008).
24. Waters CH. Diagnosis and Management of Parkinson's Disease. Professional Communications Inc., OK, USA 154-155, 195-196, 201 (2006).
25. Fahn S, Oakes D, Shoulson I et al. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351, 2498-2508 (2004).
26. Myllyla VV, Kultalahi ER, Haapaniemi H, Leinonen. FILOMEN Study Group. Twelve month safety study of entacapone in patient's with Parkinson's disease. Eur. J. Neurol. 8, 53-60 (2001).
27. Bass H, Beiske AG, Ghika J et al. Catechol-O-methyltransferase inhibition reduces the 'wearing off ' phenomenon and levodopa requirements in fluctuating parkinsonian patients. J. Neurol. Neurosurg. Psychiatry 63, 421-428 (1997).
28. Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51, 1309-1314 (1998). (Pubitemid 28520549)
29. The NINDS NET-PD Investigators. A randomized, double-blind, futility, clinical trial of creatine and minocycline in early Parkinson's disease. Neurology 66, 664-671 (2006).
30. The NINDS NET-PD Investigators. A randomized, clinical trial of coenzyme Q10 and GPI-1485 in early Parkisnon's disease. Neurology 68, 20-28 (2007).
31. Devos D; for the French DUODOPA Study Group. Patient profile, indications, efficacy, and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov. Disord. 24(7), 993-1000 (2009).
32. Holger H, Antonini A, Martinez-Martin P et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects of nonmotor symptoms and quality of life. Mov. Disord. 24(10), 1468-1474 (2009).
33. Ahlskog JE, Muenter MD. Frequency of levodopa related dyskinesia and motor complications as estimated from the cumulative literature. Mov. Disord. 16, 448-458 (2001).
34. Silver GA, Voung K, Jankovic J. Young-onset versus late-onset Parkinson's disease: clinical features and disease progression. Mov. Disord. 19(Suppl. 9), S264 (2004).
35. Waters CH. Managing the late complications of Parkinson's disease. Neurology 49(1), S49-S57 (1997).
36. Pahwa R, Factor S, Lyons KE et al. Quality Standards Subcommittee of the American Academy of Neurology Practice Parameter: treatment of Parkinson's disease with motor fluctuations and dyskinesia (an evidence based review) report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66, 983-995 (2006).
37. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord. 20, S11-S16 (2005). (Pubitemid 40846906)
38. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov. Disord. 20(5), 523-539 (2005).
39. Durif F, Vidailhet M, Assal F, Poche C, Bonnet AM, Agid Y. Low dose clozapine improves dyskinesias in Parkinson's disease. Neurology 48, 658-662 (1997). (Pubitemid 27120102)
40. Durif F, Debilly B, Galitzky M et al. Clozapine improves dyskinesias in Parkinson's disease: a double blind placebo controlled study. Neurology 62, 381-388 (2004).
41. Giladi N. Medical treatment of freezing of gait. Mov. Disord. 23(Suppl. 2), S482-S488 (2008).
42. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states. Adv. Neurol. 65, 115-138 (1995).
43. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology, and risk factors. Brain 123, 733-745 (2000). (Pubitemid 30162723)
44. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations in Parkinson's disease. Neurol. Sci. 23, 41-43 (2002). (Pubitemid 34591417)
45. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric, and motor response to galantamine in Parkinson's disease with dementia. Int. J. Geriatr. Psychiatry 18, 937-941 (2003). (Pubitemid 37294855)
46. The Parkinson Study Group. Low dose clozapine for the treatment of drug induced psychosis in Parkinson's disease. N. Engl. J. Med. 340, 757-763 (1999).
47. Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson's disease. Drugs Aging 25(8), 665-682 (2008).
48. Mancini D, Zangaglia R, Cristina S et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov. Disord. 18, 685-688 (2003). (Pubitemid 36790285)
49. Ondo WG, Hunter C, Moore W. A double-blind, placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 62, 37-40 (2004). (Pubitemid 38082867)
50. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov. Disord. 13, 895-899 (1998). (Pubitemid 28517665)
51. Kumar S, Bhatia M, Behari M. Sleep disorders in Parkinson's disease. Clin Cornerstone 6, S12-S20 (2005).
52. Rodriguez RL, Fernandez HH, Haq I, Okun MS. Pearls in patient selection in deep brain stimulation therapy. Neurologist 13, 253-260 (2007). (Pubitemid 47396311)
53. Ferraye MU, Debu B, Pollak P. Deep brain stimulation effect on freezing of gait. Mov. Disord. 23, S489-S494 (2008).
54. Weaver FM, Follett K, Stern M et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301(1), 63-73 (2009).